

August 13, 2021

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

**BSE Script Code: 531599**

**National Stock Exchange of India Ltd.**  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051

**NSE Symbol: FDC**

**Sub: Press Release**

Dear Sir/Ma'am,

Please find attached herewith the Press Release issued in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2021.

Kindly take the same on record.

Thanking you,

Yours truly

**For FDC Limited**

  
**Varsharani Katre**  
**Company Secretary**  
**F-8948**





## FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

### FDC Limited reports Q1 FY22 results

**Mumbai, 12<sup>th</sup> August, 2021:** FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the first quarter ending 30<sup>th</sup> June, 2021.

#### Consolidated Q1 FY22 FDC reported

Rs. in crores	Q1' 21-22	Q1' 20-21	YOY Growth
Operating Revenues	447.47	308.18	45.20%
EBITDA	138.67	131.55	5.41%
EBITDA %	29.46%	39.13%	-24.71%
PBT	128.30	121.36	5.72%
PAT	97.84	91.72	6.67%
EPS	5.80	5.36	8.21%

#### Commenting on the results;

We have had a good start to the financial year with a strong growth in our Domestic business, which is a big pie of our overall business. This was driven by robust demand across our established therapies and brands leading to 68% revenue growth. Our USA business portfolio saw some price erosion laid by re-entry of competitors, still our partner have been successful in maintaining good portion of market share.

The Company has been able to maintain a healthy EBITDA margin and has steadily increased over the past few years. The EBITDA margin for the quarter ended June 30, 2021 is not comparable with previous year quarter ended June 30, 2020, as during that period, certain operating expenses such as sales & marketing, travel and other plant overheads were not incurred due to Covid outbreak.

#### India Market:

Sale of branded formulations in India for Q1 FY22 was Rs. 388.47 crores, a healthy growth of 68% on YoY and 66% on QoQ. Overall sales in India market accounted for 87.24% of total consolidated sales for the quarter.

As per secondary sales data by IQVIA for the quarter ended June 30, 2021, the Company delivered a strong YoY growth of 44% compared to Indian Pharmaceutical Market (IPM) growth of 39% YoY. This growth was mainly driven by big brands like Zifi, Electral and Enerzal which witnessed a good volume growth partly helped by higher COVID-19 cases during the quarter.



CORPORATE OFFICE

REGISTERED OFFICE

: 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102, INDIA  
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2677 3462  
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com  
: B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad, INDIA  
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299  
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176

**Export Formulations Market:**

Formulation Sales in the Export market were Rs. 43.12 crores in Q1 FY22, down by 27% over YoY and down by 25% QoQ and accounted for 9.65% of total consolidated sales.

The main contributor is the USA market, accounting to 44.83% of total Export Formulations Sales.

